SecBot SecBot
SECBOTREPLAY Home › Report › LYEL

LYEL · Lyell Immunopharma reported its Q4 and full-year 2025 financial…

Lyell Immunopharma, Inc · PRESS-RELEASE filed Mar 12, 2026 at 16:05 ET

At the news

MIXEDIMPACT 6/10

PRESS-RELEASE filed Mar 12, 2026 at 16:05 ET

Lyell Immunopharma reported its Q4 and full-year 2025 financial results, highlighted by reduced net losses compared to the prior year, ongoing pivotal trials for ronde-cel in lymphoma, clinical progress with LYL273 in colorectal cancer, and a $50 million equity tranche closing. The company has $247.2 million in cash as of year-end 2025, with runway into Q2 2027.

  • Net loss narrowed to $140.7M in Q4 2025 from $191.9M in Q4 2024; full-year loss decreased to $274.4M from $343.0M in 2024.
  • Cash, cash equivalents, and marketable securities were $247.2M as of December 31, 2025, excluding $50M raised in March 2026.
  • Patient dosing has commenced in the Phase 3 head-to-head PiNACLE-H2H trial of ronde-cel vs. axi-cel or liso-cel in 2L large B-cell lymphoma.
  • Seven new patients treated with LYL273 in mCRC since acquisition, with no dose-limiting toxicity and escalation to Dose Level 3.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access